or Try an Advanced Search...

    Regulus Therapeutics Stocks List

    Symbol Grade Name % Change
    PRQR C ProQR Therapeutics B.V. -1.63
    CAPR C Capricor Therapeutics, Inc. -5.97
    SPRO F Spero Therapeutics, Inc. -0.83
    LPTX F LEAP THERAPEUTICS, INC. -0.39
    ABOS F Acumen Pharmaceuticals, Inc. -2.53
    RGLS F Regulus Therapeutics Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Alnylam Pharmaceuticals Biotechnology Oligonucleotide Alzheimer's Disease Amyloid Amyloid Beta Amyloidosis Antimicrobial Resistance Atherosclerosis Bacterial Infections Biology Blastoma Cancer Carcinoma Cardiovascular Disease Cystic Fibrosis Disease Drug Resistant Bacterial Infections Evolutionary Biology

    Related ETFs - A few ETFs which own one or more of the above listed Regulus Therapeutics stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.19
    VTWV B Vanguard Russell 2000 Value ETF 0.03
    VTWG B Vanguard Russell 2000 Growth ETF 0.03
    IWM B iShares Russell 2000 ETF 0.02
    RSSL B Global X Russell 2000 ETF 0.02
    View all Regulus Therapeutics ETFs...
    Compare ETFs
    Compare IWM to RSSL Compare VTWG to RSSL Compare VTWV to VTWG

        Regulus Therapeutics Stocks Recent News

        Date Stock Title
        Nov 21 SPRO JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
        Nov 20 CAPR Capricor wins key EU designations for the lead asset
        Nov 20 SPRO Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
        Nov 20 CAPR Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
        Nov 19 SPRO FATE Presents Encourgaing Data From Lupus Study, Stock Gains
        Nov 19 SPRO CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
        Nov 18 SPRO TenNor’s Phase III antibiotic trial meets all primary endpoints
        Nov 18 SPRO CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
        Nov 17 SPRO Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 16 CAPR Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025?
        Nov 15 CAPR Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Alnylam Pharmaceuticals Biotechnology Oligonucleotide Alzheimer's Disease Amyloid Amyloid Beta Amyloidosis Antimicrobial Resistance Atherosclerosis Bacterial Infections Biology Blastoma Cancer Carcinoma Cardiovascular Disease Cystic Fibrosis Disease Drug Resistant Bacterial Infections Evolutionary Biology
        Regulus Therapeutics

        Regulus Therapeutics Inc. or Regulus (NASDAQ: RGLS) is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals.

        More about Regulus Therapeutics
        Browse All Tags